Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".
Burlington, MA, United States.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Flexion Therapeutics is implementing good security practices.
Read more about the latest issues in cybersecurity
For many businesses, global third-party vendors have become an important source of strategic ...
Protected health information (PHI) is any information about health status, provision of health care ...
Compare Flexion Therapeutics's security performance with other companies